System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish

PubMed: 42581417 DOI: 10.1080/09546634.2026.2694924

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.

J Dermatolog Treat 37(1):2694924

Authors: April W Armstrong, Bruce E Strober, Clive M Liu, Jennifer C Cather, Joseph F Merola, Mark G Lebwohl

Affiliations

  • Division of Dermatology, University of California Los Angeles, Los Angeles, CA, USA.
  • Central Connecticut Dermatology Research, Cromwell, CT, USA.
  • Yale University, New Haven, CT, USA.
  • Bellevue Dermatology, Bellevue, WA, USA.
  • Mindful Dermatology and Modern Research Associates, Dallas, TX, USA.
  • Department of Dermatology and Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

OBJECTIVE

To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events.

METHODS

Relevant published evidence from real-world studies and clinical trials that met defined criteria was identified through targeted searches of PubMed, supplemented by manual reviews of reference lists and input from authors.

RESULTS

In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. PASI 100 was achieved by 45.5%-63.6% of patients with 26 weeks of brodalumab therapy after anti-IL-12/23, anti-IL-23, or anti-tumor necrosis factor alpha agents in a phase 4 study. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients.

CONCLUSIONS

Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent.

MeSH

Tumor Necrosis Factor-Alpha, Treatment Failure, Therapeutics, Biological Therapy, Psoriasis